Loading...
XNYS
PKI
Market cap10bUSD
, Last price  
USD
Name

Perkinelmer Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
2.55
Div Yield, %
Shrs. gr., 5y
1.95%
Rev. gr., 5y
-0.91%
Revenues
2.76b
+0.16%
1,473,831,0001,546,358,0001,787,331,0001,937,465,0001,812,202,0001,704,346,0001,921,287,0002,115,205,0002,166,232,0002,237,219,0002,262,359,0002,115,517,0002,256,982,0002,777,996,0002,883,673,0003,782,745,0005,067,169,0003,311,822,0002,750,571,0002,755,026,000
Net income
296m
-57.32%
66,532,000119,583,000131,686,000126,409,00085,599,000135,922,000174,00069,940,000167,212,000157,778,000212,425,000234,299,000156,890,000237,927,000227,558,000727,887,000943,157,000569,179,000693,094,000295,833,000
CFO
628m
+588.38%
208,093,000127,440,000205,127,000217,844,000148,722,000164,253,000224,874,000152,170,000158,591,000281,597,000287,098,000350,615,000288,453,000311,038,000363,469,000892,177,0001,410,750,000679,810,00091,272,000628,299,000
Dividend
Jul 20, 20230.07 USD/sh

Profile

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
IPO date
Jul 06, 1965
Employees
11,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,755,026
0.16%
2,750,571
-16.95%
3,311,822
-34.64%
Cost of revenue
1,629,211
1,427,458
1,543,609
Unusual Expense (Income)
NOPBT
1,125,815
1,323,113
1,768,213
NOPBT Margin
40.86%
48.10%
53.39%
Operating Taxes
33,055
3,473
129,161
Tax Rate
2.94%
0.26%
7.30%
NOPAT
1,092,760
1,319,640
1,639,052
Net income
295,833
-57.32%
693,094
21.77%
569,179
-39.65%
Dividends
(34,454)
(34,966)
(35,344)
Dividend yield
0.25%
0.26%
0.20%
Proceeds from repurchase of equity
(369,578)
(388,882)
(66,524)
BB yield
2.69%
2.85%
0.38%
Debt
Debt current
23,824
754,778
470,929
Long-term debt
3,453,486
3,476,170
4,263,283
Deferred revenue
(4,323,210)
Other long-term liabilities
770,523
930,946
4,288,185
Net debt
2,188,970
2,545,070
4,135,237
Cash flow
Cash from operating activities
628,299
91,272
679,810
CAPEX
(86,648)
(81,368)
(85,632)
Cash from investing activities
776,162
1,313,524
(132,851)
Cash from financing activities
(1,128,235)
(947,121)
(661,803)
FCF
1,341,114
580,639
2,272,563
Balance
Cash
1,163,396
1,603,079
454,358
Long term investments
124,944
82,799
144,617
Excess cash
1,150,589
1,548,349
433,384
Stockholders' equity
5,569,764
5,455,946
4,629,821
Invested Capital
10,612,613
11,320,631
11,443,086
ROIC
9.96%
11.59%
14.14%
ROCE
9.57%
10.28%
13.62%
EV
Common stock shares outstanding
122,822
124,812
126,426
Price
111.99
2.45%
109.31
-22.04%
140.22
-30.26%
Market cap
13,754,836
0.82%
13,643,200
-23.04%
17,727,454
-24.43%
EV
15,943,806
16,188,270
21,862,691
EBITDA
1,553,664
1,754,882
2,195,213
EV/EBITDA
10.26
9.22
9.96
Interest
96,278
98,813
103,955
Interest/NOPBT
8.55%
7.47%
5.88%